PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
176.45 - 178.59
86.62 - 184.48
124.91M / 173.95M (Avg.)
50.81 | 3.50
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
8.54%
Revenue growth above 1.5x TSM's 0.76%. David Dodd would confirm if the firm has a unique advantage driving sales higher.
13.64%
Gross profit growth above 1.5x TSM's 7.51%. David Dodd would confirm if the company's business model is superior in terms of production costs or pricing.
-13.86%
Negative EBIT growth while TSM is at 7.62%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-13.86%
Negative operating income growth while TSM is at 7.62%. Joel Greenblatt would press for urgent turnaround measures.
-21.22%
Negative net income growth while TSM stands at 6.06%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-18.31%
Negative EPS growth while TSM is at 5.74%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-22.54%
Negative diluted EPS growth while TSM is at 5.74%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
1.95%
Share count expansion well above TSM's 0.01%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
1.97%
Slight or no buyback while TSM is reducing diluted shares. John Neff might consider the competitor’s approach more shareholder-friendly.
No Data
No Data available this quarter, please select a different quarter.
-60.38%
Both companies show negative OCF growth. Martin Whitman would analyze broader economic or industry conditions limiting cash flow.
-65.89%
Both companies show negative FCF growth. Martin Whitman would consider an industry-wide capital spending surge or margin compression.
179.08%
Similar 10Y revenue/share CAGR to TSM's 188.06%. Walter Schloss might see both firms benefiting from the same long-term demand.
23.81%
5Y revenue/share CAGR under 50% of TSM's 62.58%. Michael Burry would suspect a significant competitive gap or product weakness.
-22.08%
Negative 3Y CAGR while TSM stands at 165.42%. Joel Greenblatt would look for missteps or fading competitiveness that hurt sales.
237.34%
OCF/share CAGR of 237.34% while TSM is zero. Bruce Berkowitz might see a slight advantage that could compound over time.
199.82%
5Y OCF/share CAGR above 1.5x TSM's 49.52%. David Dodd would confirm if the firm has better cost structures or brand premium boosting mid-term cash flow.
10.76%
3Y OCF/share CAGR under 50% of TSM's 111.62%. Michael Burry would worry about a significant short-term disadvantage in generating operational cash.
265.36%
Below 50% of TSM's 586.71%. Michael Burry would worry about a sizable gap in long-term profitability gains vs. the competitor.
30.85%
Below 50% of TSM's 77.70%. Michael Burry would worry about a substantial lag vs. the competitor’s profit ramp-up.
-28.55%
Negative 3Y CAGR while TSM is 2034.88%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
420.13%
Equity/share CAGR of 420.13% while TSM is zero. Bruce Berkowitz might see a slight advantage that can compound significantly over 10 years.
88.06%
5Y equity/share CAGR above 1.5x TSM's 25.77%. David Dodd might see stronger earnings retention or fewer asset impairments fueling growth.
17.68%
Below 50% of TSM's 36.38%. Michael Burry suspects a serious short-term disadvantage in building book value.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-1.60%
Firm’s AR is declining while TSM shows 6.89%. Joel Greenblatt sees stronger working capital efficiency if sales hold up.
10.26%
Inventory growth well above TSM's 11.75%. Michael Burry suspects overshooting production or weaker sell-through vs. the competitor.
5.37%
Asset growth at 50-75% of TSM's 7.44%. Martin Whitman questions if the firm is lagging expansions or if the competitor invests more aggressively.
6.30%
1.25-1.5x TSM's 4.98%. Bruce Berkowitz sees if the firm's capital management strategies surpass the competitor's approach.
-1.85%
We’re deleveraging while TSM stands at 41.48%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
7.40%
R&D growth drastically higher vs. TSM's 4.67%. Michael Burry fears near-term margin erosion unless breakthroughs are imminent.
-32.34%
We cut SG&A while TSM invests at 13.21%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.